Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Trial Profile

Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Facial-wrinkles; Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 19 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016.
    • 28 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 19 Jun 2015 Planned End Date changed from 1 Sep 2016 to 1 Jun 2016 as per ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top